Meeting
2023 ASCO Genitourinary Cancers Symposium
US real-world first-line (1L) treatment patterns and outcomes for patients with metastatic urothelial carcinoma (mUC) following maintenance avelumab approval.
Authors
Haojie Li
Merck & Co., Inc., Rahway, NJ
Haojie Li , Lisa Herms , Traci Leong , Paul R. Conkling , Sonia Franco , Puneet Singhal , Ronac Mamtani , Manojkumar Bupathi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 483)
DOI
10.1200/JCO.2023.41.6_suppl.483
Abstract #
483
Poster Bd #
J5
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Evolving treatment landscape in metastatic urothelial carcinoma (mUC) post-avelumab maintenance approval: Real-world insights from The US Oncology Network.
First Author: Haojie Li
Poster
2022 ASCO Genitourinary Cancers Symposium
Criteria used to determine platinum eligibility and first-line (1L) treatment (tx) patterns among platinum-eligible (PE) and -ineligible (PI) patients (pts) with metastatic urothelial cancer (mUC) in France, Germany, Spain, Italy, and the United Kingdom (Eu5).
First Author: Neil Milloy
Poster
2024 ASCO Genitourinary Cancers Symposium
Trends over time in the proportion of sequential treatment and overall survival in patients with metastatic urothelial carcinoma in real-world practice.
First Author: Shoma Yamamoto
Poster
2023 ASCO Genitourinary Cancers Symposium
Spatial immunophenotypes of distant metastases and response to immune checkpoint inhibition.
First Author: Franziska Erlmeier